NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, today announced that data from a sub-analysis of its first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) will be presented at the American Heart Association 2015 Scientific Sessions, being held November 7-11, 2015 in Orlando, Florida. Flurpiridaz F 18 is an investigational positron emission tomography (PET) MPI agent in Phase 3 development.
Help employers find you! Check out all the jobs and post your resume.
